A review of current evidence for vilazodone in major depressive disorder

  title={A review of current evidence for vilazodone in major depressive disorder},
  author={Sheng-Min Wang and Changsu Han and Soo-Jung Lee and Ashwin A. Patkar and Prakash S. Masand and Chi-Un Pae},
  journal={International Journal of Psychiatry in Clinical Practice},
  pages={160 - 169}
Abstract Objectives. This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its differential action mechanism and extended clinical utility. Methods. A data search was conducted in June 2012 using the PubMed/ MEDLINE/relevant clinical trial databases with the key terms “vilazodone” or “Viibryd.” Results. The efficacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week… 
Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
The findings indicate that the novel antidepressant vilazodone is effective and safe for MDD, with a low occurrence of side effects, and offers promise as an effective oral drug for the treatment of MDD.
Vilazodone for the Treatment of Depression: An Update
Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile and 2 RCTs recently documented the efficacy and safety of vilazdone in patients with generalized anxiety disorder, which could be a start of broadening vilazodones usage or FDA approval in diverse anxiety disorders.
Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice
The objective of the present review was to enhance clinicians' current understanding of aripiprazole augmentation and how to optimize the use of this therapy in the treatment of MDD.
Criticisms of drugs in early development for the treatment of depression: what can be improved?
An updated overview of the progress and critical limitations in the development of novel antidepressants for major depressive disorder is provided.
The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?
  • L. Dawson
  • Biology, Psychology
    Expert opinion on drug discovery
  • 2013
This review provides the history and preclinical development of vilazodone, highlighting the available data on its putative mechanism of action, potential clinical profile and possible areas for differentiation and suggests preclinical hypotheses will be contextualised with an overview of the key findings from the current clinic data on vilazdone.
Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder
MDD treatment with vilazodone was associated with significantly lower rates of inpatient and emergency services, and with significant lower all-cause medical service costs and numerically (non-significantly) lower total costs to payers than with the other SSRIs included in this study.
Comparative efficacy of selective serotonin reuptake inhibitors (SSRI) in treating major depressive disorder: a protocol for network meta-analysis of randomised controlled trials
This study aims to compare the efficacy of SSRIs by conducting a Bayesian network meta-analysis, which will be the most comprehensive evaluation of evidence to resolve the inconsistency among previous studies.
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs.
Novel and Investigational Drugs in Depression
This article will highlight new psychopharmacological agents and investigational directions which may show promise in achieving better outcomes and symptom relief for those suffering from depression.
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
  • S. Kennedy, R. Lam, R. Uher
  • Medicine, Psychology
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2016
Evidence-based pharmacological treatments are available for first-line treatment of major depressive disorder and for management of inadequate response, however, given the limitations of the evidence base, pharmacological management of MDD still depends on tailoring treatments to the patient.


Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
  • Arif Khan
  • Psychology
    Expert opinion on investigational drugs
  • 2009
Vilazodone offers a dual mechanism of action, good general tolerability with the potential for less impairment of sexual function than selective serotonin reuptake inhibitors and the possibility of personalized treatment for MDD.
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Vilazodone is effective for the treatment of MDD in adults, with symptom relief starting at 1 week, and is well tolerated at a dose of 40 mg/day, according to the intention-to-treat sample.
A 1-Year, Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder
Vilazodone 40 mg/d for 1 year was safe and well tolerated by adults with major depressive disorder and improvements in Sexual Functioning Questionnaire mean scores improved throughout treatment for both males and females.
Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
Atypical antipsychotics are effective augmentation agents in major depressive disorder but are associated with an increased risk of discontinuation due to adverse events.
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Duloxetine and Venlafaxine-XR in the Treatment of Major Depressive Disorder: A Meta-Analysis of Randomized Clinical Trials
Venlafaxine-XR tends to have a favorable trend in remission and response rates compared with duloxetine, however, dropout rates and adverse events did not differ and a direct comparison is warranted to confirm this tendency.
Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder
Current evidence does not warrant recommending a particular second-generation antidepressant on the basis of differences in efficacy, but differences in onset of action and adverse events may be considered when choosing a medication.
A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
Vilazodone 40 mg/d was well tolerated and effective in adult patients with MDD and had significantly greater improvements from baseline inHDRS-17, HDRS-21, HARS, CGI-S, and CGI-I scores than placebo patients.
The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT.
An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression.
There is much literature regarding complex medication management of major depression that is generally supportive of this practice, however, much of the literature contains underpowered and uncontrolled studies.